<DOCUMENT>
<TYPE>EX-10.232
<SEQUENCE>4
<FILENAME>a2104577zex-10_232.htm
<DESCRIPTION>EXHIBIT 10.23.2
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03WDC1176_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kz1177_exhibit_10.23.2"> </A>
<A NAME="toc_kz1177_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;10.23.2    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kz1177_amendment_no._2"> </A>
<A NAME="toc_kz1177_2"> </A>
<BR></FONT><FONT SIZE=2><B>AMENDMENT NO. 2    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;2, effective on the last date of signature, modifies and amends the Co-Promotion Agreement dated effective
November&nbsp;26, 1997, as amended by the Amendment last executed on July&nbsp;31, 2000 (together, the "AGREEMENT"), by and between Abbott Laboratories through its Ross Products Division
("ABBOTT"), and MedImmune,&nbsp;Inc. ("MEDIMMUNE"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kz1177_witnesseth"> </A>
<A NAME="toc_kz1177_3"> </A>
<BR></FONT><FONT SIZE=2><B>WITNESSETH    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, MEDIMMUNE and ABBOTT entered into a Co-Promotion Agreement dated effective November&nbsp;26, 1997 in order to co-promote the
PRODUCT in the TERRITORY, and on July&nbsp;31, 2000 entered into an Amendment effective for the 2000/2001 RSV season; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
MEDIMMUNE and ABBOTT desire to further amend the AGREEMENT in order to provide special consideration for Synagis sales; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW
THEREFORE, in consideration of the promises and of the mutual covenants and agreements herein set forth, the parties hereto agree as follows: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Unless
otherwise stated capitalized terms have the same meaning herein as ascribed to them by the AGREEMENT.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>The
term of this Amendment No.&nbsp;2 shall be for one RSV selling Season beginning on July&nbsp;1, 2001 through June&nbsp;30, 2002. Thereafter, the terms and conditions of the
Agreement shall again apply in all respects, without any affect from this Amendment No.&nbsp;2.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>During
the term of this Amendment No.&nbsp;2, the following reporting and payment compensation shall apply for the NET SALES of PRODUCT sold for use in the TERRITORY by MEDIMMUNE or
its AFFILATES as follows:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD><FONT SIZE=2>Within
thirty (30)&nbsp;days after achievement of (CONFIDENTIAL TREATMENT REQUESTED) in net sales during the term of this Amendment No.&nbsp;2 (i.e., the 2001/2002 RSV season),
ABBOTT shall pay to MEDIMMUNE (CONFIDENTIAL TREATMENT REQUESTED).
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD><FONT SIZE=2>ABBOTT
shall receive the following payment on NET SALES of PRODUCT. </FONT></DD></DL>
</DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>% Royalty</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>Threshold</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>(CONFIDENTIAL TREATMENT REQUESTED)</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Amendment No.&nbsp;2 and the AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter thereof and supersedes all prior agreements
and </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2104577",CP="MEDIMMUNE, INC.",DN="3",CHK=918199,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KZ1177A.;6',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<BR>

<P><FONT SIZE=2>
understandings in this respect. There shall be no amendments or modifications to this Amendment No.&nbsp;2 or the AGREEMENT, except by a written document which is signed by both parties. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>MEDIMMUNE,&nbsp;INC.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2>ABBOTT LABORATORIES<BR></FONT>
</TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>MELVIN D. BOOTH</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Melvin D. Booth</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>GARY FLYNN</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Gary Flynn</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
President&nbsp;&amp; Chief Operating Officer</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
Sr. Vice President</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
November&nbsp;29, 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="41%"><FONT SIZE=2><BR>
November&nbsp;16, 2001</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2104577",CP="MEDIMMUNE, INC.",DN="3",CHK=278771,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KZ1177A.;6',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03WDC1176_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kz1177_1">Exhibit 10.23.2</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kz1177_2">AMENDMENT NO. 2</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kz1177_3">WITNESSETH</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=YLEE,SEQ=,EFW="2104577",CP="MEDIMMUNE, INC.",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
